Numerous data indicate a high incidence of cardiovascular diseases against the background of a novel coronavirus infection, including initially healthy individuals. The development of complications such as cardiac rhythm disturbances, myocardial injury, acute coronary syndrome aggravates the severity of the disease and the prognosis. Moreover, signs of structural and functional damage of the cardiovascular system are detected after recovery, which makes prevention issues especially relevant. Various non-modifiable risk factors for the severe course of COVID-19, such as gender, age, heredity, race, environment, can determine the development of complications, including heart disease. In this matter, genetic characteristics are also important. The literature review presents possible genetic predictors and the mechanism of their influence on the development of cardiovascular complications and the severe course of novel coronavirus infection. The identification of specific genetic predictors can determine biological mechanisms that are relevant to diagnostic and treatment strategies. Moreover, recognizing people at high or low risk of severe COVID-19 can contribute to understanding the course of infection in different people and the development of cardiovascular complications. In addition, the determination of genetic markers contributes to the early detection of developing cardiovascular complications against the background of the novel coronavirus infection and elaboration of the personalized prevention strategy.

Direct оral Anticoagulants (DOACs) include direct thrombin inhibitor (dabigatran) and factor X inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). The) are widely used worldwide for the prevention and treatment of venous thrombosis. The popularity of DOACs is explained by convenient and predictable pharmacodynamics, the lack of need for regular monitoring of the therapeutic effect, as well as more predictable food-drug interaction and bioavailability. However, like any other anticoagulants, DOACs are characterized by an increased risk of bleeding, especially gastrointestinal one. The correct approach to the prescription of DOACs and prevention of bleeding during treatment including the intake of anticoagulants can significantly reduce the probability of life-threatening complications. In the case of bleeding, the use of specific and nonspecific DOACs antidotes is indicated. Significant bleeding requires the attending physician to know a clear course of action in accordance with published algorithms to save the patient’s life.